Beraprost sodium works by activating prostacyclin receptors on platelets and vascular smooth muscle cells, which in turn stimulates adenylate cyclase, raises intracellular cAMP levels, inhibits calcium influx, and reduces thromboxane A2 production. These actions contribute to its antiplatelet effects and vasodilation. It’s mainly used to relieve symptoms of chronic arterial occlusive disease such as ulcers, intermittent claudication, pain, and coldness.

Shuxinqing^® Beraprost Sodium Tablets were approved for marketing in March 2025. It is widely used in clinical practice and recommended in numerous domestic and international guidelines due to its excellent safety profile and minimal adverse reaction. With multiple mechanisms of action, including anti-platelet, vasodilation, smooth muscle proliferation inhibition, endothelial cell protection, and anti-inflammatory effects, it is the first-choice treatment for chronic arterial occlusion.